US Edition
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile
OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), an ocular condition characterised by chronic, nerve-related eye pain that currently lacks US Food and Drug Administration (FDA)-approved treatment. Conducted at Tufts Medical Center, Boston, US, the trial evaluated the safety and efficacy of urcosimod […] The post OKYO Pharma reports promising phase 2 results for ur…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
